S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Bed Bath & Beyond Is Circling the Drain
Pfizer Stock: What the Bulls and Bears are Getting Wrong
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Institutions are Buying up Procter & Gamble Shares, Should you?
Has The Salesforce Turnaround Begun?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Bed Bath & Beyond Is Circling the Drain
Pfizer Stock: What the Bulls and Bears are Getting Wrong
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Institutions are Buying up Procter & Gamble Shares, Should you?
Has The Salesforce Turnaround Begun?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Bed Bath & Beyond Is Circling the Drain
Pfizer Stock: What the Bulls and Bears are Getting Wrong
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Institutions are Buying up Procter & Gamble Shares, Should you?
Has The Salesforce Turnaround Begun?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Bed Bath & Beyond Is Circling the Drain
Pfizer Stock: What the Bulls and Bears are Getting Wrong
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
The Biggest "Missing Ingredient" in the $7 Trillion EV Market (Ad)
Institutions are Buying up Procter & Gamble Shares, Should you?
Has The Salesforce Turnaround Begun?
NASDAQ:CNTB

Connect Biopharma - CNTB Stock Forecast, Price & News

$1.28
+0.05 (+4.05%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.23
$1.31
50-Day Range
$0.70
$1.29
52-Week Range
$0.56
$5.10
Volume
83,725 shs
Average Volume
55,618 shs
Market Capitalization
$70.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00

Connect Biopharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
1,612.1% Upside
$22.00 Price Target
Short Interest
Healthy
0.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.76) to ($2.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

293rd out of 1,053 stocks

Pharmaceutical Preparations Industry

133rd out of 519 stocks


CNTB stock logo

About Connect Biopharma (NASDAQ:CNTB) Stock

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.

Receive CNTB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Connect Biopharma and its competitors with MarketBeat's FREE daily newsletter.

CNTB Stock News Headlines

Connect Biopharma: A Last Hurrah From CBP-307
Connect Biopharma delays pivotal study for lead candidate
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Connect Biopharma Holdings Ltd
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Connect Biopharma Holdings Ltd. ADR
See More Headlines
Receive CNTB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Connect Biopharma and its competitors with MarketBeat's FREE daily newsletter.

CNTB Company Calendar

Today
2/02/2023
Next Earnings (Estimated)
3/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CNTB
Fax
N/A
Employees
62
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.00
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+1,612.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.73 per share

Miscellaneous

Free Float
42,629,000
Market Cap
$70.78 million
Optionable
Not Optionable
Beta
-0.44

Key Executives

  • Dr. Wubin Pan M.B.A. (Age 57)
    Ph.D., Co-Founder, Pres & Chairman of Directors
  • Dr. Zheng Wei Ph.D. (Age 58)
    Co-Founder, CEO & Director
  • Mr. Steven Chan (Age 50)
    Chief Financial Officer
  • Mr. Jiang Bian J.D.
    Gen. Counsel & Chief Compliance Officer
  • Dr. Lei Sun Ph.D. (Age 58)
    VP of Biologics & Head of CMC
  • Dr. Raul Collazo Ph.D.
    VP & Global Head of Medical Affairs
  • Dr. Malinda V. Longphre Ph.D.
    Head of US Clinical Operations
  • Dr. Chin Lee M.D. (Age 52)
    M.P.H., Chief Medical Officer













CNTB Stock - Frequently Asked Questions

Should I buy or sell Connect Biopharma stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Connect Biopharma in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CNTB shares.
View CNTB analyst ratings
or view top-rated stocks.

What is Connect Biopharma's stock price forecast for 2023?

3 Wall Street research analysts have issued 1-year price targets for Connect Biopharma's shares. Their CNTB share price forecasts range from $22.00 to $22.00. On average, they anticipate the company's stock price to reach $22.00 in the next year. This suggests a possible upside of 1,612.1% from the stock's current price.
View analysts price targets for CNTB
or view top-rated stocks among Wall Street analysts.

How have CNTB shares performed in 2023?

Connect Biopharma's stock was trading at $0.8678 at the beginning of 2023. Since then, CNTB stock has increased by 48.1% and is now trading at $1.2850.
View the best growth stocks for 2023 here
.

When is Connect Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our CNTB earnings forecast
.

When did Connect Biopharma IPO?

(CNTB) raised $150 million in an initial public offering (IPO) on Friday, March 19th 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. Jefferies, VB Leerink, Piper Sandler and CICC served as the underwriters for the IPO.

What is Connect Biopharma's stock symbol?

Connect Biopharma trades on the NASDAQ under the ticker symbol "CNTB."

Who are Connect Biopharma's major shareholders?

Connect Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Connect Biopharma?

Shares of CNTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Connect Biopharma's stock price today?

One share of CNTB stock can currently be purchased for approximately $1.29.

How much money does Connect Biopharma make?

Connect Biopharma (NASDAQ:CNTB) has a market capitalization of $70.77 million.

How can I contact Connect Biopharma?

Connect Biopharma's mailing address is East R&D Building 3rd Floor Science and Technology Park 6 Beijing West Road, TAICANG F4, 215400. The official website for the company is www.connectbiopharm.com. The company can be reached via phone at 86-512-5357-7866 or via email at david.carey@finnpartners.com.

This page (NASDAQ:CNTB) was last updated on 2/2/2023 by MarketBeat.com Staff